Follow on Google News News By Tag * Hta * Payors * Clinical * Health * Drug * Nice * Patient * Assessed * Pharmaceuticals * Evidence * More Tags... Industry News News By Place Country(s) Industry News
Follow on Google News | Recently released market study: Trends in Health Technology AssessmentFast Market Research recommends "Trends in Health Technology Assessment" from Business Insights, now available
The report explores approaches to HTA, profiles HTA organizations in six countries (Australia, Canada, France, Germany, the UK, and the US) and examines how their results are used to inform pricing and reimbursement decisions. The focus is on pharmaceuticals, medical devices, and diagnostics and how the rapidly evolving HTA environment will influence future market access of these technologies. Features and benefits * Analyze what evidence is required for HTA evaluations to show that a particular drug/medtech product represents an improvement on current practice. * Gain an insight into HTA programs & identify common trends in assessment practices and areas where there are differences in processes and procedures. * Evaluate how P&R policies are influenced by HTA outcomes and what impact HTA advice has on payors and providers, supported by case studies. * Assess industry's role in providing evidence that meets diverse HTA demands. * Evaluate how interaction between regulators and payors could pave the way for greater synergies between regulatory and HTA requirements. ------------------------------------------------------------ Full Report Details at - http://www.fastmr.com/ ------------------------------------------------------------ Highlights Clinical and cost effectiveness are assessed for pharmaceuticals in Australia, Canada and the UK, while clinical benefit is the main focus in France and Germany for new drugs. CER is rapidly gaining momentum in the US to inform federal funding decisions, while commercial US payors use clinical and economic evidence in formulary listings. Patient input is gaining greater significance in HTA, helping to provide a broader perspective of a product's value in the real world setting. By February 2011, 22 drugs had benefited from the new process for patient group input during the Canadian Common Drug Review since it was introduced in May 2010. From January 2011, the clinical benefit of all new pharmaceuticals launched in Germany must be assessed on the basis on manufacturers' dossiers. The introduction of value-based pricing in the UK in 2014 will require all new brand medicines to demonstrate value, replacing the current system of selective appraisals by NICE. Your key questions answered * What factors are used by different HTA bodies to measure the costs and benefits of health technologies? * How is advice provided by HTA organizations used by different payors? * How can companies best approach the need to incorporate HTA requirements into their product development plans? * What are the key challenges of HTA and what efforts are underway to address theses? * Which organizations are involved in HTA in Australia, Canada, France, Germany, the UK, and the US? Report Table of Contents: Executive Summary Overview of health technology assessment National HTA organizations profiled HTA in practice Influence of HTA on pricing and reimbursement Industry's role in HTA Future perspectives About the author Disclaimer Overview of health technology assessment Summary Introduction Definition of HTA HTA processes Evolution of HTA Collaborative initiatives INAHTA HTAi EuroScan EUnetHTA Key HTA principles Influence of HTA on pharma/medtech National HTA organizations profiled Summary Introduction Australia PBAC MSAC PLAC Canada CADTH Provincial HTA organizations France Pharmaceutical HTA Medical device HTA MTAs Germany G-BA IQWiG DAHTA@DIMDI UK NICE technology appraisals Evaluation Pathway Program NIHR HTA US CMS AHRQ PCORI DERP Private sector HTA in practice Summary Introduction Transparency Stakeholder involvement Patient input Canada's new process for CDR Calculating cost-effectiveness NICE threshold Theoretical thresholds Cost minimization Efficiency frontier Cost-consequence analysis Timeliness of HTA Influence of HTA on pricing and reimbursement Summary Introduction Uptake of HTA advice by payors Australian government overrides PBAC advice Listing of drugs assessed centrally in Canada Dual recommendations in France Pharmaceuticals Medical devices Reassessment Germany's new early assessment procedure HTA of older products Implementation of advice by providers Future role of NICE Changing US landscape CMS coverage of Provenge Tackling uncertainty US CED Ontario's cancer drug scheme UK patient access schemes Managed entry in Australia Industry's role in HTA Summary Introduction European Tapestry Network Swiss HTA consensus Industry case study Industry relationship with payors/policy- Regulator/HTA/ UK pilot parallel scientific advice process Sweden's experience with parallel advice US collaboration Future perspectives Summary Introduction Increased scope of HTA Orphan drugs HTA as part of product development HTA and market access schemes Convergence of HTA programs EU HTA co-operation Relative effectiveness/ Summary of conclusions Appendix Scope Methodology Secondary research Glossary/Abbreviations About Business Insights Business Insights appreciate the importance of accurate, up-to-date incisive market and company analysis and their aim therefore is to provide a single, off-the-shelf, objective source of data, analysis and market insight. Business Insights work in association with leading industry experts to produce a range of reports across a wide range of industry sectors. By working in association with so many experts they are able to provide clients with more incisive market analysis specific to the client's industry sector. No other market analysis company provides such focused and trusted market analysis, across such a wide range of industry sectors. View more research from Business Insights at http://www.fastmr.com/ About Fast Market Research Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156. # # # Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available. End
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number